Comment on the Stages of HIV Care Continuum: Considering Treatment for Secondary Prevention among Patients ‘Retained in Care’
Journal Title: Journal of Clinical Research in HIV AIDS and Prevention - Year 2014, Vol 2, Issue 1
Abstract
No Abstract
Authors and Affiliations
H. Elsa Larson, S. Candace Frater, Michelle A. Lally
Keywords
Related Articles
- EP ID EP262822
- DOI 10.14302/issn.2324-7339.jcrhap-12-128
- Views 97
- Downloads 0
Determinants of Consistent Condom Use among HIV-Positive Women in Abia State, South-East Nigeria.
Background: The use of condoms in marriages is a complex decision. It however plays a role in prevention of HIV and other sexually transmitted infections (STIs). The problem is, what factors and conditions determine con...
Knowledge, Perception And Practice Of Preventive Lifestyle Against HIV/AIDS Among Students Of A Tertiary Educational Institution In South Eastern Nigeria.
HIV/AIDS has become a global scourge affecting mainly young people. Sexual behavior change remains the most effective way of preventing further spread. The aim of this study is to assess the knowledge, perception and pra...
Antiretroviral Pre-Exposure Prophylaxis Awareness, Experience and Acceptance among Men who have Sex with Men in Southwest Switzerland
Objectives Antiretroviral pre-exposure prophylaxis (PrEP) against HIV acquisition has been shown to be safe and effective in populations at risk of HIV acquisition. We examined PrEP awareness, experience and acceptance a...
Supporting Quality Data Systems: Lessons Learned from Early Implementation of Routine Viral Load Monitoring at a Large Clinic in Lilongwe, Malawi
Successful viral load programs rely on the presence of data systems and high quality of patient data. Using a cohort of 49 patients at Partners in Hope, a large, urban HIV clinic in Malawi, we performed a quality improve...
Rhabdomyolysis in a HIV-infected Patient Following the Addition of Raltegravir, A Case Report with Review of the Literature
Antiretrovirals have traditionally been associated with much toxicity. Newer antiretrovirals are considered much less toxic relative to older antiretrovirals. Upon its FDA-approval in 2009, raltegravir’s adverse drug rea...